<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876521</url>
  </required_header>
  <id_info>
    <org_study_id>AIIMS BBSR/PGThesis/2019-21</org_study_id>
    <nct_id>NCT04876521</nct_id>
  </id_info>
  <brief_title>Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression</brief_title>
  <acronym>PSD-AOFC</acronym>
  <official_title>Comparative Efficacy and Safety of Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in the Treatment of Post Schizophrenic Depression: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-Schizophrenic Depression (PSD) increases the morbidity and mortality of Schizophrenic&#xD;
      patients. Hence, it warrants early assessment and intervention. But, clinical trials on PSD&#xD;
      are very few. However, an Antipsychotic with an adjunctive Antidepressant (like&#xD;
      Olanzapine-Fluoxetine Combination) is the commonly prescribed treatment in PSD. Low dose&#xD;
      Amisulpride (&lt;400 mg/day) which is effective against the negative symptoms of Schizophrenia&#xD;
      has also proved efficacious in treating depression in non-psychotic conditions, but its&#xD;
      antidepressant property has never been studied in PSD. This is an 8-week, randomized,&#xD;
      parallel-group study that will explore the efficacy and safety of low-dose Amisulpride versus&#xD;
      Olanzapine-Fluoxetine Combination in the treatment of PSD. Our hypothesis is that low dose&#xD;
      Amisulpride has better efficacy and safety versus Olanzapine-Fluoxetine Combination in PSD,&#xD;
      after 8-weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study would be an 8-week, randomized, controlled, parallel-group, clinical trial&#xD;
      which will be conducted at the Inpatient and Outpatient settings of the Department of&#xD;
      Psychiatry, AIIMS, Bhubaneswar. Patients with the diagnosis of Post Schizophrenic Depression&#xD;
      according to the ICD 10 (DCR) and meeting all the Inclusion and Exclusion Criteria would be&#xD;
      selected for the study. At first, the patients and their family members/ guardians would be&#xD;
      explained about the study procedure along with its possible risks and benefits using a&#xD;
      Patient Information Sheet (in their local language). After obtaining a written Informed&#xD;
      Consent from the Legally Authorised Relative, the patients would be finally recruited for the&#xD;
      study.&#xD;
&#xD;
      All recruited patients would be randomized using computer-generated random numbers into two&#xD;
      treatment groups with an allocation ratio of 1:1. The sociodemographic and clinical data of&#xD;
      the patients would be collected as per the designed sheets. Then at baseline, the CDSS and&#xD;
      CGI ratings would be assessed, and the serum BDNF would be tested for each patient. The study&#xD;
      would be rater-blinded. The experimental group would receive Amisulpride at a low dosage of&#xD;
      100-300 mg/day and the control group would receive a combination of Olanzapine at 5mg or 10&#xD;
      mg/day and Fluoxetine at 20mg/day.&#xD;
&#xD;
      The two groups would be followed for 8 weeks, at the completion of which all the patients&#xD;
      would be reassessed. The follow-up assessment would involve a re-evaluation of the CDSS and&#xD;
      the CGI scores and the Serum BDNF levels to see for any change. The data thus collected would&#xD;
      be analyzed, compared within and in between the study groups and statistical tests would be&#xD;
      applied for drawing conclusions. The missing values will be analyzed by an intention-to-treat&#xD;
      protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">May 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel-group, rater-blinded, clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The proposed study will be rater-blinded. The ratings would be done by a psychiatrist who would be blinded to the nature of the intervention provided</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Calgary Depression Scale for Schizophrenia (CDSS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Calgary Depression Scale for Schizophrenia (CDSS) scores will be used to measure the change in the severity of depressive symptoms in the study groups from baseline over 8 weeks. the total score ranges from 0 - 36. Higher scores represent higher severity of depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical Global Impression (CGI) scores will be used to measure the change in illness severity, global functioning and improvement in the study groups from baseline over 8 weeks.&#xD;
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale [minimum: 1 and maximum 7]: Higher scores means higher severity of disease.&#xD;
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale [minimum: 1 and maximum 7]: Higher scores means more clinical improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum BDNF levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change in serum BDNF levels in the study groups over 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation</measure>
    <time_frame>8 week</time_frame>
    <description>Determine the correlation (if any) between the between changes in CDSS scores, CGI scores and serum BDNF levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>8 weeks</time_frame>
    <description>Detect adverse drug reactions (if any) and grading their severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post-Schizophrenic Depression</condition>
  <arm_group>
    <arm_group_label>Amisulpride Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive low dose Amisulpride at 100-300 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine-Fluoxetine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients will receive Olanzapine-Fluoxetine Combinations at 5/10-5/20 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>low dose of Amisulpride at 100-300 mg/day</description>
    <arm_group_label>Amisulpride Group</arm_group_label>
    <other_name>Sulpitac</other_name>
    <other_name>Amazeo</other_name>
    <other_name>Soltus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine-Fluoxetine Combination</intervention_name>
    <description>Olanzapine (5 mg/day) and Fluoxetine (10-20 mg/day)</description>
    <arm_group_label>Olanzapine-Fluoxetine Group</arm_group_label>
    <other_name>Oleanz Fort</other_name>
    <other_name>Oleanz Plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with Post Schizophrenic Depression according to ICD10-DCR (International&#xD;
             Classification of Diseases 10- Diagnostic Criteria for Research).&#xD;
&#xD;
          2. Aged between 18 to 60 years of either sex&#xD;
&#xD;
          3. Patients with a positive score of less than 29 on the Positive and Negative Syndrome&#xD;
             Scale (PANSS) [88]&#xD;
&#xD;
          4. Patients with a score of more than 6 on the Montgomery-Asberg Depression Rating Scale&#xD;
             (MADRS) [89-90]&#xD;
&#xD;
          5. Patients without Extrapyramidal symptoms: a score of less than 3 on the Simpson-Angus&#xD;
             Scale [91]&#xD;
&#xD;
          6. With Informed consent from the Legally Authorised Relative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a medical or neurological disorder&#xD;
&#xD;
          2. Patients with a history of substance dependence&#xD;
&#xD;
          3. Patients with high suicidality&#xD;
&#xD;
          4. Patients with a past history of primary depression&#xD;
&#xD;
          5. Patients already on Olanzapine-Fluoxetine combination or Amisulpride&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biswa R Mishra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, Bhubaneswar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rituparna Maiti, MD</last_name>
    <phone>9438884191</phone>
    <email>pharm_rituparna@aiimsbhubaneswar.edu.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tathagata Biswas, MBBS</last_name>
    <phone>9735177798</phone>
    <email>drtatz92@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>DR BISWA RANJAN MISHRA</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rituparna Maiti, MD</last_name>
      <phone>9438884191</phone>
      <email>pharm_rituparna@aiimsbhubaneswar.edu.in</email>
    </contact>
    <contact_backup>
      <last_name>Tathagata Biswas, MBBS</last_name>
      <phone>9735177798</phone>
      <email>drtatz92@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Berrios GE, Bulbena A. Post psychotic depression: the Fulbourn cohort. Acta Psychiatr Scand. 1987 Jul;76(1):89-93.</citation>
    <PMID>3630758</PMID>
  </reference>
  <reference>
    <citation>Stern MJ, Pillsbury JA, Sonnenberg SM. Postpsychotic depression in schizophrenics. Compr Psychiatry. 1972 Nov-Dec;13(6):591-8.</citation>
    <PMID>4637572</PMID>
  </reference>
  <reference>
    <citation>Rahim T, Rashid R. Comparison of depression symptoms between primary depression and secondary-to-schizophrenia depression. Int J Psychiatry Clin Pract. 2017 Nov;21(4):314-317. doi: 10.1080/13651501.2017.1324036. Epub 2017 May 15.</citation>
    <PMID>28503978</PMID>
  </reference>
  <reference>
    <citation>Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med. 2003 May;33(4):589-99. Review.</citation>
    <PMID>12785461</PMID>
  </reference>
  <reference>
    <citation>Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990 Jul-Aug;3(4):247-51.</citation>
    <PMID>2278986</PMID>
  </reference>
  <reference>
    <citation>MÃ¶ller HJ. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. Review.</citation>
    <PMID>14642970</PMID>
  </reference>
  <reference>
    <citation>Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA, Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010 Sep;11(6):763-73. doi: 10.3109/15622971003611319.</citation>
    <PMID>20334574</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>BISWA RANJAN MISHRA</investigator_full_name>
    <investigator_title>Additional Professor, Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Post-Schizophrenic Depression</keyword>
  <keyword>Amisulpride</keyword>
  <keyword>Olanzapine-Fluoxetine Combination</keyword>
  <keyword>Post Psychotic Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It will be discussed among investigators later.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

